Recovery In Vitro Research Only

TB-500: Systemic Recovery, Muscle Repair & Cardiovascular Healing

43 Amino Acid Thymosin Beta-4 Analogue

TB-500 is the synthetic form of Thymosin Beta-4 (Tβ4), a naturally occurring 43-amino-acid peptide encoded by the TMSB4X gene and found in virtually every human cell. Unlike BPC-157's localized action, TB-500 operates systemically — mobilizing stem cells, regulating actin polymerization, and driving body-wide tissue repair signaling. It is one of the few peptides with Phase I/II human clinical data from RegeneRx Biopharmaceuticals.

For in vitro laboratory research use only. Not for human consumption. All findings described are from preclinical or in vitro models.

MECHANISMS OF ACTION

In vitro and preclinical mechanistic observations

🧬

Actin Sequestration & Cell Migration

Tβ4's primary role is sequestering G-actin monomers, controlling polymerization that governs cell migration and wound closure at the molecular level.

❤️

Cardiac Progenitor Stem Cell Activation

Activates dormant epicardial progenitor stem cells post-myocardial infarction, promoting cardiomyocyte regeneration and measurable improvement in ejection fraction.

🛡️

Anti-Fibrotic Signaling

Downregulates myofibroblast differentiation — the primary driver of scar formation — with documented activity in cardiac, hepatic, and cutaneous fibrosis models.

🔬

NF-κB & Cytokine Suppression

Reduces NF-κB signaling and pro-inflammatory cytokines including IL-1β and TNF-α while simultaneously promoting angiogenesis in ischemic tissue.

KEY RESEARCH DATA

Quantitative findings from published preclinical research

💊

Phase II

Human Clinical Trials

RegeneRx Biopharmaceuticals

🩺

Amino Acids

TMSB4X gene encoded

🔬

Fibrosis Models Studied

Cardiac, hepatic, skin, corneal

🧪

Systemic

Mechanism Reach

Body-wide vs. localized

Wound Healing Improvement Rates — TB-500 vs. Placebo (% change from baseline)

Pressure Ulcers

Venous Stasis

Corneal Epithelium

Cardiac EF

Skin Wound Rate

Data compiled from Philp et al. (2004) Ann NY Acad Sci and Sosne et al. (2007) Arch Ophthalmol Phase I/II human trials.

PRECLINICAL SAFETY PROFILE

Observed tolerability data from in vitro and animal model research

96%

Tolerability

Low Severity

Injection-Site Rxn

Low Severity

Theoretical Risk

Low Severity

Safety data reflects preclinical observations only. Human clinical safety profiles may differ substantially. For in vitro laboratory research use only. Not for human consumption.